{
  "ptid_time": "012_S_4849_2012-07-24",
  "img_path": "/data/qiuhui/data/adni/images/012_S_4849/2012-07-24/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 16,521 mm³, 26.0% below the reference mean. With a Z-score of -0.65 (25.7th percentile), this represents normal volume ; hippocampal volume measures 6,707 mm³, 12.7% below the reference mean. With a Z-score of -1.43 (7.7th percentile), this represents mild atrophy; whole brain volume measures 947,602 mm³, 7.9% below the reference mean. With a Z-score of -0.99 (16.2th percentile), this represents normal volume ; entorhinal cortex volume measures 2,918 mm³, 25.0% below the reference mean. With a Z-score of -1.94 (2.6th percentile), this represents moderate atrophy; fusiform gyrus volume measures 17,360 mm³, 4.7% below the reference mean. With a Z-score of -0.53 (30.0th percentile), this represents normal volume ; middle temporal gyrus volume measures 16,434 mm³, 19.9% below the reference mean. With a Z-score of -1.77 (3.8th percentile), this represents moderate atrophy. ",
  "text_data": "Age is 65.9 years. Gender is Female. Education: 18 years. Handedness: Right. Race: White. Medical history: Psychiatric; Cardiovascular; Musculoskeletal; Renal-Genitourinary. MMSE: 29.0. MoCA: 28.0. Logical Memory: 10.0. APOEε4 alleles: 2.0. Biomarker levels: Florbetapir (AV45): 1.45 SUVR (significant elevated); Amyloid beta: 691.30 pg/mL (normal ); Total tau: 277.30 pg/mL (normal ); Phosphorylated tau: 26.90 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging shows mild to moderate atrophy in the hippocampus, entorhinal cortex, and middle temporal gyrus—key regions affected in Alzheimer’s disease. However, cognitive scores (MMSE 29, MoCA 28) are intact, and CSF biomarkers (Aβ, T-tau, P-tau) are normal despite elevated AV45 (amyloid PET), suggesting early amyloid deposition without significant neurodegeneration or cognitive impairment.  \n\n**Diagnosis:** **CN (Cognitively Normal)**  \n**Confidence:** **Medium** (Conflicting evidence: amyloid positivity and focal atrophy vs. normal cognition and CSF biomarkers. Early preclinical AD is possible, but current data do not meet MCI/dementia criteria.)  \n\n---  \n*Note:* If longitudinal follow-up shows cognitive decline, reclassification to MCI would be warranted. The APOE4 homozygosity (2 alleles) and elevated AV45 suggest high risk for future progression.",
  "timestamp": "2025-07-25T23:16:20.857375"
}